Filed with the SEC on · Summarized by InvestorsBot
Regeneron Pharmaceuticals director Michael S. Brown sold 1,929 shares of common stock in an open-market transaction at $875.00 per share on October 30, 2026. The sale was valued at approximately $1,687,875, and Brown owned 1,380 shares after the transaction.
Pick up to 20 companies — we read their SEC filings overnight and send you the plain-English version. Free.
Subscribe freeRegeneron reports 36% revenue growth and raises several 2026 cost targets
8-K · October 30, 2026
Regeneron co-chief scientific officer sells about $3.2M in stock
Form 4 · Insider Trade · October 15, 2026
Regeneron grants CEO and CSO 10-year performance share awards
8-K · September 30, 2026
Regeneron EVP McCourt sells about $2.0 million in stock
Form 4 · Insider Trade · September 3, 2026
Regeneron Posts 17% Revenue Growth and Raises 2026 Profitability Guidance
8-K · July 30, 2026
Regeneron filed an 8‑K (Item 9.01) on Jan 30, 2026: Exhibit 99.1 = press release reporting Q4 & full‑year…
8-K · January 30, 2026